GlassScriptPhysician profile
Joleen M Volz
NPI 1487711347
$50,571.62
in general payments reported to CMS, 2019-2025
30 companies · $8,686 in 2025
The $8,686 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,917 · 2022: $12K · 2023: $16K · 2024: $11K · 2025: $8,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,840 · Travel and Lodging: $1,930 · Education: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,236.00 |
| Food and Beverage | $12,782.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,840.00 |
| Travel and Lodging | $1,929.59 |
| Education | $757.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $12,722.58 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $6,277.31 | 2021-2025 | Levulan Kerastick, Absorica Ld, Winlevi |
| Incyte Corporation | $5,960.73 | 2021-2025 | Opzelura |
| Ucb, INC. | $5,330.83 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $3,606.99 | 2021-2025 | Sotyktu |
| Leo Pharma INC. | $3,452.39 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $2,098.78 | 2021-2025 | |
| Janssen Biotech, INC. | $1,778.09 | 2021-2025 | Tremfya, Remicade, Simponi |
| Amgen INC. | $1,576.58 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,462.23 | 2021-2025 | |
| Epi Health, LLC | $1,024.57 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,010.06 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $843.33 | 2021-2025 | |
| Dermavant Sciences, INC. | $781.89 | 2022-2024 | Vtama |
| Lilly USA, LLC | $562.54 | 2021-2025 | Olumiant, Ebglyss, Taltz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $467.29 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Prugen, INC. Pharmaceuticals | $350.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $328.29 | 2021-2024 | Siliq, Arazlo, Cabtreo |
| Sanofi-Aventis U.S. LLC | $181.55 | 2021 | |
| Journey Medical Corporation | $165.48 | 2022-2023 | |
| Pfizer INC. | $148.68 | 2021-2025 | |
| Organon LLC | $134.08 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.54 | 2023-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $75.90 | 2021-2024 | |
| Almirall LLC | $40.68 | 2024 | Seysara |
| Celgene Corporation | $26.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.17 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $20.01 | 2025 | Acthar |
| Botanix Sb INC | $16.85 | 2025 | Sofdra |
| Biofrontera INC. | $10.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joleen Volz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.